10 Real-World AI Agent Use Cases in Pharma, MedTech, and Diagnostics

Most of the AI running inside healthcare today sits on the clinical side. MedTech Dive’s tracker of the FDA’s AI device list counts more than 1,400 authorized AI-enabled devices since 1995, with 331 cleared in 2025 alone, the highest single year on record. Radiology triage and pathology screening now sit inside routine practice, regulated and largely finished being argued about.

Almost none of it has reached the commercial side of those same companies. Deciding which physicians to call on, or where to put the next three field reps, still happens on the back of exports, ticket queues, and an analyst who is booked until Thursday.

When those teams do reach for a general-purpose model, they hit the wall immediately. Ask one which interventional cardiologists in Arizona perform the most of a given procedure and it will produce a list of plausible names with NPI numbers attached, none of which survive a check against the registry.

AI agents change that, though only under a specific condition.

An agent takes a question in plain language and works out for itself which steps it needs, querying whatever systems it can reach before handing back something you can act on. Its value is set entirely by what it is allowed to look up.

A governed source of US provider and claims data gets you correct answers in seconds. Absent that, the model fills gaps with invention, and the invention is fluent enough to clear a first read.

The ten use cases below are grouped by the kind of company you work in. A pharma launch team, a device manufacturer moving off distributors, and an independent reference lab do not share a commercial model, so the questions they put to an agent are barely interchangeable.

How AI Agents Support Commercial Teams Across Healthcare

The commercial function in life sciences runs on a small set of repeating questions. How many providers fit this profile, where are they, what do they actually do, and who else is already talking to them.

Answering any of them means pulling records, filtering against clinical criteria, then reconciling identifiers before anything can be formatted and passed on. That work absorbs the hours of people who were hired for judgment it never actually calls on.

Agents Absorb the Retrieval Work

An agent is good at the part of the job that has a verifiable right answer. Counting providers who bill a specific CPT code in a defined geography falls squarely inside that description. Judgment calls sit outside it, including whether the resulting segment justifies a dedicated sales team at all.

The distinction matters more in healthcare than in most industries, because a provider count can be wrong in two ways that both read as clean output. An ungrounded agent invents entries that clear a first read, and even a grounded one returns the wrong set if it applied the wrong clinical criteria.

Neither error is visible in the answer itself. A rep drives to a clinic, discovers the practice does not perform the procedure, and the cost surfaces two weeks later as a missed quarter.

Teams that get value out of agents draw the line early. Retrieval, counting, cross-referencing, and first drafts all go to the agent. Everything downstream belongs to a person who reads the output and checks which criteria were applied before acting on any of it. Compliance reviewers accept that split far more readily than they accept full delegation.

Vertical Structure Decides What an Agent Is Worth

Pharma commercial teams sell through prescribing behavior, mediated at every step by formulary placement and prior authorization. For a device manufacturer the unit of sale is a procedure, which happens inside a particular room in a particular building, so geography is inescapable.

Diagnostics has the hardest version of the problem, because a test that is indicated but never ordered leaves no trace. That underordering is both the larger and the harder-to-detect share of inappropriate testing, it runs at roughly 45% of cases, close to double the overutilization rate, and is driven more by whether a physician recalls the test at the point of care than by any clinical disagreement.

The order turns on the physician thinking of the test while the patient is still in front of them, which is exactly the failure a specialty roster can’t see.

AI Agent Use Cases in Pharma Commercial Operations

Pharma commercial work has gotten harder to model in the last two years. Pricing has stopped being a purely manufacturer decision. Launch windows have compressed at the same time that coverage friction became something payers are required to publish plan by plan.

The four use cases here are where the gap between question asked and answer received has been costing the most.

1. Sizing an Indication Before Launch Budget Is Committed

Brand teams routinely commit headcount and media spend against a market estimate built from a specialty proxy. Every endocrinologist becomes a proxy for every patient with the condition, which overstates some geographies badly and misses the primary care physicians carrying real volume elsewhere.

An agent connected to diagnosis-level claims data answers the question directly. You ask how many providers treated patients with a given ICD-10 code in the last year, ranked by volume and split by state, and get a count grounded in billed encounters rather than a specialty roster.

The number changes the shape of the launch plan, because indication density and specialty density rarely sit in the same places.

2. Rebuilding Commercial Assumptions When a Product Enters Price Negotiation

Medicare price negotiation has moved from a policy question to an operating input. In January 2026, CMS selected 15 drugs for the third negotiation cycle, the first cycle to include Part B drugs, covering roughly 1.8 million Medicare enrollees and about $27 billion in spending, close to 6% of combined Part B and Part D spend.

When a product lands on that list, the commercial team has to rework its assumptions fast. Which prescribers carry the most Medicare-weighted volume becomes urgent, and so does the question of where Part B administration physically happens once infusion sites enter the picture.

An agent that can query prescriber and procedure data on demand turns a multi-week analyst project into a working session. Teams handling market access and pricing strategy can iterate on those cuts in the same conversation instead of queuing three separate requests.

3. Reading Payer Friction Into Field Priorities

Coverage friction has become visible in a way it was not before. Under the CMS Interoperability and Prior Authorization final rule, impacted payers must publicly report annual prior authorization metrics including approval rates, denial rates, outcomes after appeal, and average decision time, with API requirements phasing in through 2027.

For a brand team, that public reporting is a targeting signal. A provider whose patients sit in plans with slow authorization turnaround needs heavier support material and a longer call cadence than one whose patients clear in days.

An agent can hold provider list, geography, and plan mix in a single query and hand back a prioritized view, which leaves field leadership free to do the interpreting.

4. Sequencing Launch Geographies Against Diagnosis Concentration

Launch sequencing usually follows population size or existing rep coverage, both of which are proxies for the thing that actually matters. The better ordering follows where the diagnosed, treated patients sit and which providers are already managing them.

Asked to rank metropolitan areas by treated patient volume for a specific set of diagnosis codes, an agent returns a sequence in minutes. That output is not a plan on its own. It gives the commercial lead an evidence-backed starting point for the argument with finance, which is usually the harder half of the job.

AI Agent Use Cases for MedTech Sales and Market Access

Device commercial teams have a geography problem that pharma does not. Every procedure happens in a physical location, and those locations have been moving steadily out of the hospital while purchasing authority drifts away from the surgeon toward whoever employs them.

Agents help most where those pressures meet.

5. Following Procedures as They Move Out of the Hospital

Site of care is shifting under device manufacturers faster than most territory models update. In the CY 2026 OPPS and ASC final rule, CMS added 289 procedures to the ambulatory surgical center covered procedures list and moved another 271 codes off the inpatient-only list, a substantial expansion of what can be done outside a hospital.

If your device supports any of those procedures, your account list is now partly wrong. An agent that can query sites of care by procedure code tells you which ASCs in a territory already perform the relevant work and at what volume, which is the difference between calling on a surgery center that is ready and one that has never billed the code.

Running that check quarterly instead of annually is realistic once it takes a question rather than a project.

6. Treating the Employer as the Account

Independent practice has become the exception. The PAI and Avalere Health report covering 2018 through 2026 found that 82.0% of US physicians are now employed by hospitals or corporate entities, and 63.9% of physician practices are owned by them, with rural markets tracking the same direction at 80.2% employment.

A target list of individual physicians tells you who uses your device. The buyer is somewhere else in the org chart. An agent that resolves providers to their affiliations and sites of care lets a rep see the whole employed group standing behind a high-volume surgeon before the first call, which changes who gets contacted and in what order.

Account maps go stale faster than most CRM refresh cycles allow for, and an agent makes rebuilding them cheap enough to do on schedule.

7. Auditing Distributor Coverage Against Real Procedure Volume

Manufacturers selling through distributors are working with reported coverage rather than observed coverage. When a distributor reports that a territory is penetrated, nothing in that statement is checkable against the claims record, which shows exactly which providers in the territory perform the procedure and at what frequency.

An agent can produce that comparison on request, setting total addressable procedure volume in a distributor region, ranked by account, against the accounts actually generating orders.

The reason the gap persists is structural. In a distributor model the distributor owns the invoice and the end-account relationship, so the manufacturer sees what it ships in and whatever the distributor chooses to report back instead of the account-level procedure volume underneath.

The party describing the coverage is the same party whose incentive is to look fully penetrated.
And the blind spot is not marginal. In Model N’s 2026 State of Revenue report, roughly nine in ten medtech leaders said they lack real-time visibility into their own revenue data across the channel.

The claims record is the one independent view of which providers actually performed the procedure and how often, which makes it the only place a coverage story gets confirmed or punctured. That is the underlying question in both the distributor audit and the move to direct, whether the reported coverage survives contact with the billing record.

AI Agent Applications in Diagnostics and Laboratory Organizations

Labs and diagnostics companies sell into a fragmented ordering base, and the ordering decision is made by a physician who has to think of the test at the right moment. Commercial teams here work with thinner markets and less margin for a wasted call than either pharma or device.

8. Finding the Ordering Physicians Behind a Test Menu

A lab’s sales team knows its menu in CPT terms. Translating that menu into a list of physicians whose patients need those tests is the work that eats the week. Specialty is a poor filter, because the physicians ordering high-complexity molecular pathology are scattered across oncology, gastroenterology, and primary care depending on the region.

An agent queried against procedure and diagnosis data reverses the problem. You describe the test menu, it returns the providers whose billing patterns indicate the underlying patient population, ranked by volume. A rep walking in already knowing that a practice bills several hundred relevant screens a month has a different conversation than one opening with a brochure.

9. Sizing a Thin Specialty Market Before Building a Sales Team

Specialty labs face a structural constraint. A genetic testing business cannot market to primary care generally, and the number of clinics that genuinely need its assay may be in the low hundreds nationally. Getting that number wrong in either direction is expensive.

The NIH Genetic Testing Registry holds information on genetic tests covering more than 22,000 phenotypes, which gives some sense of how finely this market subdivides.

The Association for Diagnostics and Laboratory Medicine has separately noted how central laboratory developed tests have become to diagnosis in oncology and inherited disease.

An agent that can count providers against a narrow diagnosis and procedure profile gives a founder or commercial lead a defensible market size before the first sales hire, rather than after.

10. Tracking Where Test Volume Settles After a Regulatory Shift

Regulatory changes redistribute volume, and diagnostics has just been through one. A federal court vacated the FDA’s laboratory developed tests rule in March 2025, and the FDA subsequently reverted the regulation to its prior text in September 2025.

The Congressional Research Service summary lays out what that leaves in place, with CLIA rather than the device framework governing these tests.

Commercial teams need visibility into where testing volume actually moved afterward and which laboratories and physician groups absorbed it, which is the only reliable way to tell whether an account list still describes the market.

An agent that can pull current billing patterns by procedure code and site of care answers that question repeatedly, at whatever interval the market is moving.

Best Practices for Implementing AI Agents in Healthcare Organizations

Most failed agent pilots in life sciences fail for the same reason. The team gave the agent an interesting question before giving it anything reliable to read.

Federal guidance has converged on the same lesson, with HHS issuing its AI Strategy in December 2025 in response to OMB Memorandum M-25-21 alongside a Health Sector AI request for information that drew comments centered on transparency, while the CDC’s own AI strategy puts governance ahead of capability.

A handful of practices separate the deployments that survive a compliance review from the ones that get quietly shelved.

• Start with questions that have a verifiable answer. Counts, rankings, and lists let an analyst confirm the output in twenty minutes, which buys the credibility you need before anyone lets an agent near a workflow that matters, whereas a strategic recommendation cannot be checked on any timescale that helps you decide whether to trust the system.

• Govern the data source before you govern the model. You need to know which dataset the agent reads, how recently it was refreshed, and whether access is scoped to your organization’s entitlements, because an open standard such as the Model Context Protocol moves data between systems and takes no position on whether that data is any good.

• Keep a person on anything that touches an HCP. Drafting outreach, sequencing accounts, and queueing records are reasonable to delegate, but sending is a different category of action for medical affairs teams working on the scientific side of the commercial firewall, so build approval steps in from the start rather than retrofitting them after legal reviews your pilot.

How Alpha Sophia Powers Healthcare AI Agent Workflows

Every use case above depends on the agent having somewhere accurate to look. Alpha Sophia is that layer.

Reasoning stays with the agent and the decision stays with your team, while Alpha Sophia supplies the external, NPI-anchored reference the agent reads from whenever a question involves real US providers, procedures, and volumes.

What the Agent Reads When It Answers a Provider Question

The foundation is a national all-payor view of US medical claims spanning commercial, Medicare including Medicare Advantage, and Medicaid, covering 4 million or more providers across every specialty and state. Layered on top are the attributes commercial teams actually filter by.

Procedures as CPT and HCPCS Level II codes, diagnoses as ICD-10 codes and CCSR categories, provider taxonomy and specialty, organizational affiliations and sites of care, prescribing behavior, open payments, education, publications, and clinical trial activity.

The ten use cases above draw on different parts of that foundation. Site of care questions run almost entirely on affiliations. Indication sizing depends on ICD-10, and a distributor audit needs that same procedure volume resolved down to the account level.

Because all of it comes from one governed source, the numbers in one answer reconcile with the numbers in the next.

Three Ways Teams Connect Their Agents

The in-app Assistant turns plain-English questions into filtered provider and site-of-care lists inside the platform, showing the criteria it applied.

Teams that would rather work in their own AI can connect Claude, ChatGPT, or Cursor to the same data over MCP for healthcare commercial intelligence.

At the far end sit fully autonomous workflows, where an agent sizes a market, builds a list, and hands the output to your CRM and email without anyone opening the app.

Marketing teams building audiences and cohorts tend to start with the Assistant and move to their own stack once the question patterns stabilize.

Where Alpha Sophia Stops

Alpha Sophia supplies the external reference, and your systems own what happens to it from there.

If you use it to check CRM records, the match, merge, and survivorship logic stays inside your CRM or MDM tooling, with Alpha Sophia acting as the authority those records get compared against.

The same boundary holds on the workflow side. Your agent orchestrates and your team approves, while the data layer confines itself to answering questions without inventing providers, NPIs, or volumes it cannot find.

Conclusion

The gap between commercial and clinical AI adoption in healthcare comes down to grounding rather than capability.

When a commercial model has no provider data underneath it, the failure takes a quarter to surface, which is why so many life sciences teams ran pilots on ungrounded models and walked away unconvinced.

The capability itself is fine for the work described here, on one condition. At the moment someone asks, your agent has to be able to retrieve an NPI that exists, with procedure volumes and a site of care attached to it that are equally verifiable.

Solve that connection problem and market sizing turns into something you settle between meetings rather than a two-week analyst project.

The alternative is an agent that keeps producing plausible numbers, and plausible numbers cost a good deal more than having none.

FAQs

What are the most common AI agent use cases in healthcare?
Clinical deployments are dominated by imaging triage, diagnostic support, and documentation. Commercially, the most common uses are market sizing, provider and site-of-care identification, account mapping, and prioritization for field teams. The commercial applications depend on the agent having access to governed provider and claims data.

How are pharma companies using AI agents today?
Pharma commercial teams mainly use them for indication sizing against diagnosis-level claims data and for reworking targeting assumptions when pricing or coverage shifts. Ranking launch geographies by treated patient volume is another common application.

How do AI agents help MedTech commercial teams?
Device teams track procedures migrating to ambulatory surgical centers and resolve individual surgeons to the health systems or corporate groups employing them. Comparing distributor-reported coverage against observed procedure volume is a third common application. All of it depends on affiliation and site-of-care data rather than provider lists alone.

What role do AI agents play in diagnostics organizations?
The most common application is translating a test menu into a list of likely ordering physicians. Labs also lean on agents to size narrow specialty markets before hiring sales staff and to monitor where testing volume settles after a regulatory or reimbursement change. T

What healthcare data do AI agents need to deliver accurate insights?
Agents need NPI-anchored provider records, all-payor claims covering procedures and diagnoses, provider taxonomy, and organizational affiliations tied to sites of care. Without that foundation, a general-purpose model will generate provider names and volumes that look correct and are fabricated.

How does Alpha Sophia support AI agent use cases in healthcare?
Alpha Sophia acts as the external reference layer an agent reads from, built on all-payor US claims across 4 million or more providers with procedure, diagnosis, affiliation, prescribing, and research attributes. Teams reach it through the in-app Assistant, through their own AI assistant over MCP, or through fully autonomous workflows.